Astrazeneca Ab

Rise Research Institutes of Sweden Ab

Nicox S.a.

Martin Hedberg

Vern Delisser

Per Olof Ryberg

Marco Villa

Per-Olov Bergstr&ouml;m

Mona Lindstr&ouml;m

Andreas Rådevik

Christian Bernlind

Swantje Thiering

Annette Jansson

Erica St&aring;hle

Aldo Belli

Vincenzo Cannata

Andreas Westermark

Telly Fonduca

A lignocellulosic starting material can be converted into an aqueous phase and a hydrocarbon phase in a one-step process by subjecting a mixture of the lignocellulosic starting material, an amorphous and unsupported sulfided nickel-molybdenum catalyst, and optionally a co-feed, to not less than a stoichiometric amount of hydrogen, elevated pressure and a temperature in the interval of 350-450° C. A novel catalyst for use in said process and a method for its production are also disclosed.

Process for one-step conversion of lignocellulosic material to hydrocarbon products and catalyst for use in said process

The present invention relates to a new process for the manufacture of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base and pharmaceutically acceptable salts thereof, particularly the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, and to new intermediates prepared in said process suitable for large scale manufacturing of said compound.

[object Object]

This invention relates to a novel form of a scrotonin h5-HT -receptor antagonist, namely a novel form of a salt of (R)-N-&lsqb;5-methyl-8-(4-methylpiperazin-1-yl)-1,2,2,4-tetrahydro-2-naphtyl&rsqb;-4-morpholinobenzamide referred to as (R)-N-&lsqb;5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl&rsqb;-4-morpholinobenzamide monohydrobromide Form A. The invention also relates to processes for preparation of said of Form A, which form has a potential use after suitable pharmaceutical formulation in medical treatment, preferably in CNS disorders, over active bladder or vasospam, or growth control of tumors.

Form of (R)-N-&lsqb;5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl&rsqb;-4-morpholinobenzamide

Growing community of inventors

Södertälje, Sweden

Martin Hedberg